ALK and non-small cell lung carcinoma: Additionally, a phase I study evaluating the efficacy and safety of lorlatinib in ALK/ROS1-positive NSCLC showed encouraging results in either ALK rearrangement or ROS1 rearrangement patients regardless of treatment lines [132].